Global Hemophilia B Market

Global Hemophilia B Market

Global Hemophilia B Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Without enough factor IX, the blood cannot clot properly to control bleeding. Hemophilia B is classified as mild, moderate or severe based on the activity level of factor IX. In mild cases, bleeding symptoms may occur only after surgery, injury or a dental procedure. In some moderate and most severe cases, bleeding symptoms may occur after a minor injury or spontaneously, meaning without an identifiable cause.

Hemophilia B is caused by changes (variants or mutations) in the factor IX gene (F9) on the X chromosome. Hemophilia B is most commonly identified in males; however, females who carry the gene may have mild or, rarely, more severe symptoms of bleeding and should have their factor IX level checked.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of hemophilia B condition

The global hemophilia B prevalence is boosting the market, with increased awareness and improved diagnostic capabilities leading to more cases being identified and treated. For instance, according to NCBI article 2023, Hemophilia occurs worldwide at a rate of 1 in 125,000. The prevalence of hemophilia B is 3.8 per 100,000 live males and 5 per 100,000 males at birth. The incidence is equal among all ethnic groups. Consanguinity can significantly contribute to frequency increases within specific communities.

Furthermore, the global Hemophilia B is also driven by various other factors like advancement in treatment options, gene therapy innovations, rise in healthcare expenditure and others help the market to grow during the forecast period.

High cost of treatment

The market for Hemophilia B is expected to be significantly impacted by factors like the high cost of treatment where, High costs of hemophilia B treatment, including factor replacement therapy, may restrict access for some patients and impose financial strain on healthcare systems. For instance, in December 2022, the US Food and Drug Administration (FDA) approved the first gene therapy for the genetic blood-clotting disorder haemophilia B—a one-time treatment that costs US$3.5 million.

Segment Analysis

The global hemophilia B market is segmented based on therapy type, severity type, end-user and region.

The replacement therapy from the therapy type segment accounted for approximately 42.1% of the Hemophilia B market share

The replacement therapy from the therapy type segment accounted for approximately 42.1%. The goal of hemophilia B replacement therapy is to achieve a plasma FIX level of 60%-80% for major bleeds and 20%-40% for minor bleeds. High-purity pdFIX concentrates are commercially available, but safety has improved over the last 20 years due to multiple viral inactivation and purification steps.

For instance, in May 2022, Precision BioLogic Inc, a leading developer of hemostasis diagnostic products, stated the launch of its new CRYOcheck Chromogenic Factor IX assay in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to the factors like high demand of disease-specific treatments, the rise in adoption of newer technologies and others that help the region to have the highest market share during the forecast period.

For instance, in June 2023, Global biotechnology leader CSL Behring stated that the first patient has received U.S. Food and Drug Administration (FDA) approved HEMGENIX (etranacogene dezaparvovec-drlb) for hemophilia B in the United States. HEMGENIX is the first and only gene therapy for the treatment of adults with haemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening bleeding, or have repeated, serious spontaneous bleeding episodes.

Covid 19 Impact Analysis

COVID-19 has significantly impacted global industry growth, leading to drug launch cancellations and clinical trial delays. Research is being conducted to understand the relationship between COVID-19 and haemophilia diseases, as well as the correlation of mortality rates in patients.

Market Segmentation

By Therapy Type
• Replacement Therapy (On-demand)
• Prophylaxis
• Gene Therapy



By Severity Type
• Mild Hemophilia B
• Moderate Hemophilia B
• Severe Hemophilia B

By End User
• Hospitals
• Speciality clinics
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Takeda Pharmaceutical Company Limited, Sobi, Genentech USA, Inc., Novo Nordisk, Pfizer Inc., CSL Behring LLC, Grifols, Octapharma USA Inc., UBI Pharma Inc., Biogen among others.

Key Developments

 In November 2022, U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Why Purchase the Report?
• To visualize the global Hemophilia B market segmentation based on therapy type, severity type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of Hemophilia B market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global Hemophilia B market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies